Institut Gustave Roussy
http://www.gustaveroussy.fr
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Institut Gustave Roussy
Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
Exelixis Makes The Case For Early Filing Of Cabozantinib In Frontline Kidney Cancer
Company recruited clinical experts to explain why Phase II CABOSUN should be enough for approval and why a Phase III study is now impractical.
Life Science Start-Ups: Tech Transfer Deals, May 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2014.
Company Information
- Industry
- Academic and Research Institutions
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice